流行病學所Hung, Chin-ChuanChin-ChuanHungTai, John JenJohn JenTaiKao, Pi-JuPi-JuKaoLin, Min-ShungMin-ShungLinLiou, Horng-HueiHorng-HueiLiou2008-10-202018-06-292008-10-202018-06-292007http://ntur.lib.ntu.edu.tw//handle/246246/83969Objectives: The aim of this study was to investigate whether the polymorphisms in the NR112 and ABCB1 genes were associated with epilepsy treatment responses. Methods & results: NR112 and ABCB1 polymorphisms were genotyped in 114 drug-resistant epileptic patients, 213 seizure-free patients and 287 normal controls. Highly specific real-time PCR was applied to detect the variants by using TaqMan allelic specific probe. For a single gene test, it was demonstrated that 3435C>T in the ABCB1 gene had a significant effect on epilepsy treatment responses, but polymorphisms in the NR112 gene did not. Further analysis using a logistic regression model revealed that only 2677G>T and 3435C>T in the ABCB1 gene and their interaction term were associated with drug-resistant epilepsy after adjustment for etiology and epilepsy classification. In the present study, the polymorphisms in the NR112 gene were not significantly associated with epilepsy treatment responses. Conclusion: Our results indicated that 2677G>T and 3435C > T in the ABCB1 gene contributed to drug-resistant epilepsy. Although biologically plausible, the polymorphisms in NR112 investigated in the present study did not play a role in epilepsy treatment responses. Other unveiled genetic variants in the NR112 gene that may have the potential to affect ABCB1 gene expression are worth further investigation in future studies.en-USABCB1drugresponseintractable epilepsymultidrug resistancepharmacogeneticsPXRjournal article